Although the activation of the cGAS-STING signaling pathway has been tested as a potential cancer immunotherapy (see Therapeutic Strategies in Tumor Immunotherapy), the potential negative tumorigenic effects of overactivation of the cGAS signaling cannot be ignored. This evidence concerns the gene STING1 and cancer.